Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Detalles Bibliográficos
Autores principales: Concordet, Didier, Gandia, Peggy, Montastruc, Jean-Louis, Bousquet-Mélou, Alain, Lees, Peter, Ferran, Aude A., Toutain, Pierre-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007421/
https://www.ncbi.nlm.nih.gov/pubmed/31802398
http://dx.doi.org/10.1007/s40262-019-00851-4
_version_ 1783495315095027712
author Concordet, Didier
Gandia, Peggy
Montastruc, Jean-Louis
Bousquet-Mélou, Alain
Lees, Peter
Ferran, Aude A.
Toutain, Pierre-Louis
author_facet Concordet, Didier
Gandia, Peggy
Montastruc, Jean-Louis
Bousquet-Mélou, Alain
Lees, Peter
Ferran, Aude A.
Toutain, Pierre-Louis
author_sort Concordet, Didier
collection PubMed
description
format Online
Article
Text
id pubmed-7007421
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70074212020-02-24 Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?” Concordet, Didier Gandia, Peggy Montastruc, Jean-Louis Bousquet-Mélou, Alain Lees, Peter Ferran, Aude A. Toutain, Pierre-Louis Clin Pharmacokinet Letter to the Editor Springer International Publishing 2019-12-05 2020 /pmc/articles/PMC7007421/ /pubmed/31802398 http://dx.doi.org/10.1007/s40262-019-00851-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Concordet, Didier
Gandia, Peggy
Montastruc, Jean-Louis
Bousquet-Mélou, Alain
Lees, Peter
Ferran, Aude A.
Toutain, Pierre-Louis
Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_full Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_fullStr Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_full_unstemmed Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_short Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_sort authors’ reply to nicolas: “why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one?”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007421/
https://www.ncbi.nlm.nih.gov/pubmed/31802398
http://dx.doi.org/10.1007/s40262-019-00851-4
work_keys_str_mv AT concordetdidier authorsreplytonicolaswhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT gandiapeggy authorsreplytonicolaswhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT montastrucjeanlouis authorsreplytonicolaswhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT bousquetmeloualain authorsreplytonicolaswhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT leespeter authorsreplytonicolaswhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT ferranaudea authorsreplytonicolaswhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT toutainpierrelouis authorsreplytonicolaswhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone

Ejemplares similares